Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TERN Terns Pharmaceuticals, Inc.

Not Yet Opened 11-25 16:00:00 EST

5.79

+0.00

0.00%

盘后5.79

+0.000.00%

18:49 EST

High5.96	Low5.71	Vol1.03M
Open5.95	D1 Closing5.79	Amplitude4.32%
Mkt Cap491.80M	Tradable Cap336.59M	Total Shares84.94M
T/O6.04M	T/O Rate1.78%	Tradable Shares58.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TERN","market":"US","secType":"STK","nameCN":"Terns Pharmaceuticals, Inc.","latestPrice":5.79,"timestamp":1732568400000,"preClose":5.79,"halted":0,"volume":1033844,"hourTrading":{"tag":"盘后","latestPrice":5.79,"preClose":5.79,"latestTime":"18:49 EST","volume":15815,"amount":91532.5904,"timestamp":1732578581530},"delay":0,"floatShares":58132695,"shares":84938855,"eps":-1.178042,"marketStatus":"Not Yet Opened","change":0,"latestTime":"11-25 16:00:00 EST","open":5.95,"high":5.96,"low":5.71,"amount":6036070.5903652,"amplitude":0.043178,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.178042,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":5.79,"preHourTrading":{"tag":"盘前","latestPrice":5.86,"preClose":5.79,"latestTime":"09:18 EST","volume":541,"amount":3229.8800394,"timestamp":1732544308237},"postHourTrading":{"tag":"盘后","latestPrice":5.79,"preClose":5.79,"latestTime":"18:49 EST","volume":15815,"amount":91532.5904,"timestamp":1732578581530},"volumeRatio":0.670758,"impliedVol":0.7799,"impliedVolPercentile":0.2262},"requestUrl":"/m/hq/s/TERN","defaultTab":"news","newsList":[{"id":"2485218264","title":"Terns Pharmaceuticals on the Brink of Innovation with Upcoming TERN-701 Data Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2485218264","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485218264?lang=en_us&edition=fundamental","pubTime":"2024-11-23 03:06","pubTimestamp":1732302403,"startTime":"0","endTime":"0","summary":"Analyst Silvan Tuerkcan from JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report) and keeping the price target ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-on-the-brink-of-innovation-with-upcoming-tern-701-data-release?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-on-the-brink-of-innovation-with-upcoming-tern-701-data-release?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2484982972","title":"Terns Pharmaceuticals Appoints Heather Turner to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2484982972","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484982972?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:50","pubTimestamp":1731966647,"startTime":"0","endTime":"0","summary":"The latest update is out from Terns Pharmaceuticals ( ($TERN) ). Terns Pharmaceuticals has announced the appointment of Heather Turner, a seasoned ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/terns-pharmaceuticals-appoints-heather-turner-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/terns-pharmaceuticals-appoints-heather-turner-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2484989309","title":"Terns Pharmaceuticals Appoints Heather Turner, J.d., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2484989309","media":"THOMSON REUTERS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484989309?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA30TWGN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2484895159","title":"Press Release: Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2484895159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484895159?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience. FOSTER CITY, Calif., Nov. 18, 2024  -- Terns Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Heather Turner, J.D., former Chief Executive Officer at Carmot Therapeutics, Inc., to the Company's Board of Directors, effective immediately. In conjunction with Ms. Turner's appointment, Ann E. Taylor, M.D., is stepping down from the Board of Directors following more than three years of service.Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2484964549","title":"Steven Cohen's Strategic Acquisition in Terns Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2484964549","media":"GuruFocus","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484964549?lang=en_us&edition=fundamental","pubTime":"2024-11-16 23:01","pubTimestamp":1731769319,"startTime":"0","endTime":"0","summary":"Overview of the Recent Transaction On September 30, 2024, Point72, led by Steven Cohen (Trades, Portfolio), executed a significant transaction by acquiring 2,894,093 shares of Terns Pharmaceuticals In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2607116/steven-cohens-strategic-acquisition-in-terns-pharmaceuticals-inc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"1172748139","title":"Stock Track | Terns Pharmaceuticals Plummets 6.56% on Kennedy's Potential HHS Appointment, Opposition to Weight-Loss Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1172748139","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172748139?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:24","pubTimestamp":1731687881,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals, Inc., a biopharmaceutical company developing an oral weight-loss drug, saw its stock plummet 6.56% in intraday trading on Friday, November 15th, as the market reacted to the potential appointment of Robert F. Kennedy Jr. as the head of the Department of Health and Human Services .Kennedy, who has been named as President-elect Donald Trump's pick for HHS secretary, is a firm opponent of the new class of weight-loss and diabetes-management drugs known as GLP-1s. He has argue","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Terns Pharmaceuticals Plummets 6.56% on Kennedy's Potential HHS Appointment, Opposition to Weight-Loss Drugs","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TERN"],"gpt_icon":0},{"id":"2483309140","title":"RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309140","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483309140?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:19","pubTimestamp":1731687540,"startTime":"0","endTime":"0","summary":"Trump's pick for head of HHS is a firm opponent of the new drugs for weight loss and diabetes management. The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.Kennedy is an opponent of GLP-1 drugs, which he has argued are the wrong approach to tackling the obesity crisis. Instead, he has said, the government should promote healthy eating, which would be far less expensive than the drugs, which cost thousands of dollars.Eli Lilly & Co. Inc.  and Denmark's Novo Nordisk  , the two leaders in the GLP-1 space, are pushing to expand insurance coverage for the drugs and have been studying how they achieve benefits beyond weight loss, such as in treating cardiovascular disease and sleep apnea.Kennedy famously blames unhealthy food, unnecessary medicines, including certain vaccines, and fl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","BK4588","IE00B4R5TH58.HKD","TERN","LU1804176565.USD","BK4581","LU1868837136.USD","BK4532","BK4534","IE0002141913.USD","LU0289739699.SGD","GPCR","LU2237443895.HKD","LU2237443549.SGD","LU1061106388.HKD","LU0256863902.USD","LU2089984988.USD","LLY","IE00BK4W5M84.HKD","LU0097036916.USD","LU0466842654.USD","IE0009355771.USD","LU0882574139.USD","SRRK","LU0820561909.HKD","LU2491050154.USD","LU2361044865.SGD","SG9999015978.USD","LU0471298777.SGD","LU2106854487.HKD","BK4585","IE00B2B36J28.USD","LU2237443382.USD","LU1974910355.USD","SG9999015952.SGD","VKTX","LU2491049909.HKD","LU1983299246.USD","AMGN","LU0256863811.USD","LU2324357040.USD","LU2361044949.HKD","NVO","LU1623119135.USD","SGXZ57979304.SGD","IE00BJLML261.HKD","LU0122379950.USD","IE00BFTCPJ56.SGD","IE0004445239.USD","LU2468319806.SGD"],"gpt_icon":1},{"id":"2483862755","title":"Promising Phase 1/2 Study and Strong Financials Drive Buy Rating for Terns Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2483862755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483862755?lang=en_us&edition=fundamental","pubTime":"2024-11-14 08:25","pubTimestamp":1731543915,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on TERN stock, giving a Buy rating yesterday. Ritu Baral has given his Buy rating d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-phase-1-2-study-and-strong-financials-drive-buy-rating-for-terns-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-phase-1-2-study-and-strong-financials-drive-buy-rating-for-terns-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN"],"gpt_icon":0},{"id":"2483585501","title":"Terns Pharmaceuticals Is Maintained at Neutral by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483585501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483585501?lang=en_us&edition=fundamental","pubTime":"2024-11-14 03:01","pubTimestamp":1731524460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TERN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 14:01 ET (19:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN"],"gpt_icon":0},{"id":"2483009135","title":"Terns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483009135?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:16","pubTimestamp":1731500188,"startTime":"0","endTime":"0","summary":"Etzer Darout, an analyst from BMO Capital, has initiated a new Buy rating on Terns Pharmaceuticals (TERN). Etzer Darout’s rating is based on a comb...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-promising-clinical-developments-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-promising-clinical-developments-and-strong-financial-position-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN"],"gpt_icon":0},{"id":"2483708720","title":"Terns Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $7.5 From $5.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2483708720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483708720?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:11","pubTimestamp":1731496284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nAZN2M5VB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2483104974","title":"Terns Pharmaceuticals: Promising Oncology Developments and Strategic Pipeline Diversification Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2483104974","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483104974?lang=en_us&edition=fundamental","pubTime":"2024-11-13 13:45","pubTimestamp":1731476733,"startTime":"0","endTime":"0","summary":"Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Terns Pharmaceuticals (TERN – Research Report), retaining the price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-promising-oncology-developments-and-strategic-pipeline-diversification-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/terns-pharmaceuticals-promising-oncology-developments-and-strategic-pipeline-diversification-justify-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN"],"gpt_icon":0},{"id":"2483064256","title":"Terns Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483064256","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483064256?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:15","pubTimestamp":1731453356,"startTime":"0","endTime":"0","summary":"* Terns Pharmaceuticals Inc    reported a quarterly adjusted loss of 28 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -42","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN"],"gpt_icon":0},{"id":"2483406607","title":"Terns Pharma Q3 EPS $(0.28) Beats $(0.34) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406607","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483406607?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:32","pubTimestamp":1731450727,"startTime":"0","endTime":"0","summary":"Terns Pharma Q3 EPS $(0.28) Beats $(0.34) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41924234/terns-pharma-q3-eps-0-28-beats-0-34-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Terns Pharma Q3 EPS $(0.28) Beats $(0.34) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TERN"],"gpt_icon":0},{"id":"2483066563","title":"Terns Pharmaceuticals reports Q3 EPS (28c), consensus (32c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483066563","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483066563?lang=en_us&edition=fundamental","pubTime":"2024-11-13 06:15","pubTimestamp":1731449734,"startTime":"0","endTime":"0","summary":"“Our progress in the third quarter was highlighted by the compelling topline results from our Phase 1 study of TERN-601, which demonstrated class-l...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/terns-pharmaceuticals-reports-q3-eps-28c-consensus-32c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/terns-pharmaceuticals-reports-q3-eps-28c-consensus-32c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TERN"],"gpt_icon":0},{"id":"2483529090","title":"BRIEF-Terns Pharmaceuticals Q3 Net Income USD -21.945 Million Vs. IBES Estimate USD -25.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483529090","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483529090?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445550,"startTime":"0","endTime":"0","summary":"Nov 12  - Terns Pharmaceuticals Q3 operating expenses USD 24.939 million.Q3 pretax profit USD -21.883 million vs. IBES estimate USD -25.7 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nPLX988CFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2483523980","title":"Terns Pharmaceuticals Q3 Operating Expenses USD 24.939 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2483523980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483523980?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445505,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nPLX988CFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TERN","BK4007"],"gpt_icon":0},{"id":"2483526010","title":"Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483526010","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483526010?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Interim data from initial dose escalation cohorts of Phase 1 CARDINAL trial evaluating TERN-701  in chronic myeloid leukemia  expected in early December 2024. Plans to initiate Phase 2 clinical trial for TERN-601 in obesity in early 2Q25 with initial 12-week data expected in 2H25. Cash, cash equivalents and marketable securities of $372.8 million, including $172.7 million equity raise in September, expected to provide runway into 2028. FOSTER CITY, Calif., Nov. 12, 2024  -- Terns Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates.TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor  for chronic myeloid leukemia . Interim data from initial dose escalation cohorts in Terns’ ongoing Phase 1 CARDINAL study of TERN-701 in CML expected in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B6BCQsYDKvl65S1UDszPGQ--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/611bda6becb939fc9cd754fdd8c57d0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B6BCQsYDKvl65S1UDszPGQ--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/611bda6becb939fc9cd754fdd8c57d0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/terns-pharmaceuticals-reports-third-quarter-210500879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4181","BK4160","BK4166","TERN","BK4007","BK4503","GIPR","QD","PK","BK4218"],"gpt_icon":0},{"id":"2481951578","title":"Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2481951578","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481951578?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:05","pubTimestamp":1730927100,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Nov. 06, 2024  -- Terns Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in November.UBS Global Healthcare ConferenceFormat: Fireside Chat Date and Time: Wednesday, November 13, 2024 at 8:45 a.m. PTLocation: Terranea Resort, Rancho Palos Verdes. Jefferies London Healthcare Conference Format: Fireside Chat Date and Time: Tuesday, November 19, 2024 at 5:00 p.m. GMT Location: Waldorf Hilton, London","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B6BCQsYDKvl65S1UDszPGQ--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/611bda6becb939fc9cd754fdd8c57d0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B6BCQsYDKvl65S1UDszPGQ--~B/aD00NDU7dz0xMTQ3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/611bda6becb939fc9cd754fdd8c57d0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/terns-pharmaceuticals-participate-upcoming-november-210500402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","TERN"],"gpt_icon":0},{"id":"2479084914","title":"Oppenheimer Initiates Terns Pharmaceuticals at Outperform With $17 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2479084914","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479084914?lang=en_us&edition=fundamental","pubTime":"2024-10-31 21:00","pubTimestamp":1730379604,"startTime":"0","endTime":"0","summary":"Terns Pharmaceuticals (TERN) has average rating of outperform and price targets ranging from $5.50 to $30, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TERN","OPY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ternspharma.com","stockEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":-0.1319},{"period":"3month","weight":-0.2717},{"period":"6month","weight":-0.1422},{"period":"1year","weight":0.477},{"period":"ytd","weight":-0.1079}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.141347},{"month":2,"riseRate":0.666667,"avgChangeRate":0.019834},{"month":3,"riseRate":0.25,"avgChangeRate":-0.017285},{"month":4,"riseRate":0.25,"avgChangeRate":-0.147316},{"month":5,"riseRate":0.5,"avgChangeRate":-0.034474},{"month":6,"riseRate":0.5,"avgChangeRate":0.026968},{"month":7,"riseRate":0.25,"avgChangeRate":-0.141552},{"month":8,"riseRate":0.5,"avgChangeRate":0.334699},{"month":9,"riseRate":0.5,"avgChangeRate":0.083337},{"month":10,"riseRate":0.5,"avgChangeRate":-0.011712},{"month":11,"riseRate":0.25,"avgChangeRate":-0.097694},{"month":12,"riseRate":0.666667,"avgChangeRate":0.235006}],"exchange":"NASDAQ","name":"Terns Pharmaceuticals, Inc.","nameEN":"Terns Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Terns Pharmaceuticals, Inc.(TERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Terns Pharmaceuticals, Inc.,TERN,Terns Pharmaceuticals, Inc.股票,Terns Pharmaceuticals, Inc.股票老虎,Terns Pharmaceuticals, Inc.股票老虎国际,Terns Pharmaceuticals, Inc.行情,Terns Pharmaceuticals, Inc.股票行情,Terns Pharmaceuticals, Inc.股价,Terns Pharmaceuticals, Inc.股市,Terns Pharmaceuticals, Inc.股票价格,Terns Pharmaceuticals, Inc.股票交易,Terns Pharmaceuticals, Inc.股票购买,Terns Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Terns Pharmaceuticals, Inc.(TERN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Terns Pharmaceuticals, Inc.(TERN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction